

BIOLOGICS AND BIOSIMILARS & BIOPHARMA & BIOTHERAPEUTICS

October 24-25, 2018 | Boston, USA



Himabindu Gaddipati

Elixsys Inc., USA

Enabling a global collaborative ecosystem in the realm of biopharma

The current era of rapidly evolving technology, market trends and policy is creating an increasingly fragmented biopharma value chain. End-to-end research or comprehensive development of a life science product which was once accomplished within an institution or organization is now being facilitated by multiple parallel interactions. Integrating diverse technology and expertise between an array of varied stakeholders across organizational and geographical boundaries is now becoming the norm. However, the logistics required to support a streamlined mechanism to facilitate more effective and efficient interaction and breakdown inter-organizational silos is largely deficient. This is especially relevant in the dynamic arena of cancer research and product development which is being accelerated by the utilization of cutting-edge technology. The solution likely lies in creating a niche environment with the required resources that will bring together diverse stakeholders along the biopharma value chain such as institutions, pharma and biotech companies, foundations and hospitals in a streamlined manner. The participants can leverage complementary skills and knowledge to amalgamate their capabilities towards unified objectives. Towards this vision, our organization has developed a novel online platform, designed to bring together diverse stakeholders across the cancer care continuum. This is an integrative “Virtual Ecosystem” that will connect groups of organizations worldwide to create “Interlinked Clusters” of concentrated knowledge, expertise and resources. The cloud-based platform enables users to review domain-specific expertise of others and initiate communication with the potential partner(s). The platform is specifically designed to integrate and streamline all activity amongst group members throughout the process of preliminary exploration, sourcing/raising funds, strategic planning and execution of a project. Ultimately this will empower stakeholders along the lifecycle to conduct synchronized initiatives on a global scale. Immense value can be generated by creating such cohesive mechanisms to enhance cost and time efficiency while reducing redundancy.

Biography

Himabindu Gaddipati is a medical oncologist based in San Diego, CA. Her varied background has provided her with a comprehensive understanding of the biopharma lifecycle encompassing basic research, product development, regulatory and Intellectual property and practical translational into the clinical realm. Following medical school, she pursued Internal Medicine residency followed by fellowships in Genetics and Molecular Biology from the University of Pennsylvania and Hematology/Oncology from University Hospitals/Case Western Reserve. She served as a visiting scientist at the Wistar Research Institute. She gained valuable insight about the regulatory requirements for marketing approval of drugs as a reviewer in the division of oncology at the US FDA. At the National Cancer Institute, she served as an analyst for the Federal Small Business Innovation Research (SBIR Program) and also completed a certificate program in Technology Transfer. She completed her Master's degree in Business and Technology Management from the Wharton School of Business. She is currently the co-chair for the Biocom oncology group, a network of more than 120 organizations including hospitals, research institutions, companies and foundations engaged in cancer-related activities in Southern California. Her company Elixsys is committed to facilitating engagement between diverse stakeholders who are engaged in oncology product discovery, development and commercialization.

Hima.g@elixsys.com

Notes: